NCT03126266

Re-Irradiation of Progressive or Recurrent DIPG

Completed NA Last updated 5 December 2024

What this trial tests

NA trial testing re-irradiation in Recurrent or Progressive Diffuse Intrinsic Pontine Glioma in 27 participants. Completed in 25 November 2024.

Timeline

15 April 2017

Primary endpoint
20 November 2024

25 November 2024

Quick facts

Lead sponsor	University of Calgary
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	15 April 2017
Primary completion	20 November 2024
Estimated completion	25 November 2024
Sites	18 locations across New Zealand, Canada, Australia

Drugs / interventions tested

• re-irradiation

Conditions studied

• Recurrent or Progressive Diffuse Intrinsic Pontine Glioma — all drugs for Recurrent or Progressive Diffuse Intrinsic Pontine Glioma →

Sponsor

University of Calgary

Who can join

Eligibility, any sex, with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review.
   Gallitto M, Lazarev S, Wasserman I, Stafford JM, et al · · 2019 · cited 73× · PMID 31360809 · DOI 10.1016/j.adro.2019.03.009
2. Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.
   Di Ruscio V, Del Baldo G, Fabozzi F, Vinci M, et al · · 2022 · cited 34× · PMID 36140466 · DOI 10.3390/diagnostics12092064
3. Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials.
   Damodharan S, Lara-Velazquez M, Williamsen BC, Helgager J, et al · · 2022 · cited 28× · PMID 35629262 · DOI 10.3390/jpm12050840
4. Immunotherapy approaches for the treatment of diffuse midline gliomas.
   Bernstock JD, Hoffman SE, Kappel AD, Valdes PA, et al · · 2022 · cited 27× · PMID 36185807 · DOI 10.1080/2162402x.2022.2124058
5. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
   van den Bent M, Saratsis AM, Geurts M, Franceschi E. · · 2024 · cited 25× · PMID 38102230 · DOI 10.1093/neuonc/noad220
6. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
   Noon A, Galban S. · · 2023 · cited 22× · PMID 37030112 · DOI 10.1016/j.neo.2023.100899
7. Radiotherapy for Diffuse Intrinsic Pontine Glioma: Insufficient but Indispensable.
   Kim HJ, Suh CO. · · 2023 · cited 17× · PMID 37151149 · DOI 10.14791/btrt.2022.0041
8. Re-irradiation for high-grade gliomas: Has anything changed?
   García-Cabezas S, Rivin Del Campo E, Solivera-Vela J, Palacios-Eito A. · · 2021 · cited 15× · PMID 34631441 · DOI 10.5306/wjco.v12.i9.767